GURUFOCUS.COM » STOCK LIST » Latin America » Mexico » MEX » Biogen Inc (MEX:BIIB) » Definitions » Accumulated Depreciation
Switch to:

Biogen (MEX:BIIB) Accumulated Depreciation

: MXN-39,983 Mil (As of Mar. 2023)
View and export this data going back to 2013. Start your Free Trial

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Biogen's quarterly accumulated depreciation increased from Sep. 2022 (MXN-42,201 Mil) to Dec. 2022 (MXN-42,222 Mil) but then stayed the same from Dec. 2022 (MXN-42,222 Mil) to Mar. 2023 (MXN-39,983 Mil).

Biogen's annual accumulated depreciation increased from Dec. 2020 (MXN-35,454 Mil) to Dec. 2021 (MXN-41,163 Mil) and increased from Dec. 2021 (MXN-41,163 Mil) to Dec. 2022 (MXN-42,222 Mil).


Biogen Accumulated Depreciation Historical Data

The historical data trend for Biogen's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Accumulated Depreciation
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -35,291.95 -30,004.37 -35,453.51 -41,163.39 -42,222.49

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Accumulated Depreciation Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -41,454.70 -42,871.46 -42,201.27 -42,222.49 -39,983.06

Biogen Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.


Biogen Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Biogen's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (MEX:BIIB) Headlines